Effect of neoadjuvant therapy on breast cancer biomarker profile

Breast cancer clinical management requires the assessment of hormone receptors (estrogen (ER) and progesterone receptor (PR)), human epidermal growth factor receptor 2 (HER2) and cellular proliferation index Ki67, by immunohistochemistry (IHC), in order to choose and guide therapy according to tumor biology. | Effect of neoadjuvant therapy on breast cancer biomarker profile

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG